Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efbemalenograstim alfa - Evive Biotech

Next Previous
X
Search
Drug Profile

Efbemalenograstim alfa - Evive Biotech

Alternative Names: Benegrastim - Evive Biotech; Bineuta; F-627; rh G-CSF dimer; rh G-CSF Fc Fusion Protein; Ryzneuta

Latest Information Update: 19 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Generon (Shanghai) Corporation
  • Developer Evive Biotech
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Immunoglobulin Fc fragments; Recombinant fusion proteins
  • Mechanism of Action Granulocyte colony stimulating factor replacements; Granulocyte colony-stimulating factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neutropenia
  • Discontinued Parkinson's disease

Most Recent Events

  • 11 Jul 2024 Launched for Neutropenia (Chemotherapy-induced) in European Union, USA, China (SC), prior to July 2024 (Evive Biotech pipeline, July 2024)
  • 15 Apr 2024 Shandong University in collaboration with Chia Tai Tianqing Pharmaceutical initiates enrollment in a phase II trial for Neutropenia (Chemotherapy induced, Prevention) in China (SC, injection) (NCT06251947)
  • 24 Mar 2024 Registered for Neutropenia (In the elderly, Chemotherapy-induced, In adults) in Norway, Iceland, Liechtenstein, European Union (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top